Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 34 of 34 results for enzalutamide

  1. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued Reference number: GID-TA11004

    Technology appraisal guidance
    Discontinued

  3. Thousands could benefit from new take-at-home treatment for advanced prostate cancer

    NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.

    News
    Last updated
    23 January 2026

  4. NICE's backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions

    Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.

    News
    Last updated
    30 October 2025